JP2013522367A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522367A5
JP2013522367A5 JP2013501396A JP2013501396A JP2013522367A5 JP 2013522367 A5 JP2013522367 A5 JP 2013522367A5 JP 2013501396 A JP2013501396 A JP 2013501396A JP 2013501396 A JP2013501396 A JP 2013501396A JP 2013522367 A5 JP2013522367 A5 JP 2013522367A5
Authority
JP
Japan
Prior art keywords
cem
diffraction pattern
powder diffraction
ray powder
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522367A (ja
JP5711352B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/029424 external-priority patent/WO2011119604A1/en
Publication of JP2013522367A publication Critical patent/JP2013522367A/ja
Publication of JP2013522367A5 publication Critical patent/JP2013522367A5/ja
Application granted granted Critical
Publication of JP5711352B2 publication Critical patent/JP5711352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501396A 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用 Active JP5711352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014231987A Division JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用

Publications (3)

Publication Number Publication Date
JP2013522367A JP2013522367A (ja) 2013-06-13
JP2013522367A5 true JP2013522367A5 (cg-RX-API-DMAC7.html) 2014-05-15
JP5711352B2 JP5711352B2 (ja) 2015-04-30

Family

ID=44673574

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013501396A Active JP5711352B2 (ja) 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Country Status (19)

Country Link
US (4) US8975386B2 (cg-RX-API-DMAC7.html)
EP (2) EP3009442B1 (cg-RX-API-DMAC7.html)
JP (4) JP5711352B2 (cg-RX-API-DMAC7.html)
KR (2) KR102006200B1 (cg-RX-API-DMAC7.html)
CN (2) CN103080122A (cg-RX-API-DMAC7.html)
AU (2) AU2011232627B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012023950A2 (cg-RX-API-DMAC7.html)
CA (1) CA2793884C (cg-RX-API-DMAC7.html)
DK (1) DK2550286T3 (cg-RX-API-DMAC7.html)
ES (1) ES2564097T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160168T1 (cg-RX-API-DMAC7.html)
IL (1) IL222018B (cg-RX-API-DMAC7.html)
MX (1) MX361413B (cg-RX-API-DMAC7.html)
MY (1) MY162411A (cg-RX-API-DMAC7.html)
NZ (1) NZ602544A (cg-RX-API-DMAC7.html)
PL (1) PL2550286T3 (cg-RX-API-DMAC7.html)
RU (1) RU2650883C2 (cg-RX-API-DMAC7.html)
SI (1) SI2550286T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011119604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080391A2 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
JP5698979B2 (ja) 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
HRP20160222T1 (hr) 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
WO2011032052A1 (en) 2009-09-10 2011-03-17 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
KR102006200B1 (ko) 2010-03-22 2019-08-01 셈프라 파마슈티컬스, 인크. 매크로라이드의 결정 형태들 및 그 용도들
EP2571506B1 (en) 2010-05-20 2017-05-10 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
KR20130120458A (ko) 2010-09-10 2013-11-04 셈프라 파마슈티컬스, 인크. 질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en) 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
EP2968801B1 (en) 2013-03-14 2018-09-26 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
AU2014248014B2 (en) 2013-04-04 2018-11-08 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
RU2017104163A (ru) * 2014-08-05 2018-09-06 Семпра Фармасьютикалз, Инк. Порошкообразные составы пероральных суспензий антибактериальных агентов
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
JP2017531663A (ja) 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ １４員ケトライドならびにそれらの調製および使用の方法
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
WO2017061431A1 (ja) * 2015-10-05 2017-04-13 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
TW201811811A (zh) * 2016-09-02 2018-04-01 森普拉製藥公司 製備氟酮內酯之方法
IL293115A (en) 2019-12-02 2022-07-01 Aliquantumrx Inc Salts and polymorphs of cethromycin for the treatment of disease Salts and polymorphs of cethromycin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
IL128681A0 (en) 1996-09-04 2000-01-31 Abbott Lab 6-O substituted ketolides having antibacterial activity
EP0988308A1 (en) 1997-06-11 2000-03-29 Pfizer Products Inc. 9-oxime erythromycin derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
ATE344269T1 (de) 1998-12-10 2006-11-15 Pfizer Prod Inc Carbamat und carbazat ketolid antibiotika
EP1147121B1 (en) 1999-01-27 2003-12-17 Pfizer Products Inc. Ketolide antibiotics
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
AU4354900A (en) 1999-04-16 2000-11-02 Kosan Biosciences, Inc. Ketolide antibacterials
AU773678B2 (en) 1999-04-16 2004-06-03 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
ES2242668T3 (es) * 2000-03-15 2005-11-16 Hanmi Pharm. Co., Ltd. Metodo para obtener claritromicina en cristales de forma ii.
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
EP1320355B1 (en) 2001-05-18 2006-04-05 Chiron Corporation System for delivering a tobramycin formulation
EP1404693A2 (en) 2001-07-03 2004-04-07 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
AR038576A1 (es) 2002-02-22 2005-01-19 Pharmacia Corp Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio
ES2346646T5 (es) 2002-05-30 2018-02-15 The Scripps Research Institute Ligación catalizada con cobre de azidas y acetilenos
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
WO2004080391A2 (en) * 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
WO2004096823A2 (en) 2003-04-25 2004-11-11 Chiron Corporation Novel ketolide derivatives
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
PL1742957T3 (pl) 2004-04-28 2008-05-30 Alembic Ltd Sposób otrzymywania telitromycyny
US20080287376A1 (en) 2004-07-28 2008-11-20 Mohammad Salman Ketolide Derivatives as Antibacterial Agents
HRP20100253T1 (hr) * 2004-12-21 2010-06-30 Pfizer Products Inc. Makrolidi
DE602006016231D1 (de) 2005-01-14 2010-09-30 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
US20070167382A1 (en) * 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
JP5698979B2 (ja) * 2007-10-25 2015-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド系抗菌剤の調製プロセス
US20110040078A1 (en) * 2007-10-25 2011-02-17 Siegfried Wolf Process for the production of telithromycin
HRP20160222T1 (hr) * 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
KR102006200B1 (ko) * 2010-03-22 2019-08-01 셈프라 파마슈티컬스, 인크. 매크로라이드의 결정 형태들 및 그 용도들

Similar Documents

Publication Publication Date Title
JP2013522367A5 (cg-RX-API-DMAC7.html)
JP2012144574A5 (cg-RX-API-DMAC7.html)
PH12014500164A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
JP2013525444A5 (cg-RX-API-DMAC7.html)
WO2013040286A3 (en) Pharmaceutical compositions
WO2012021796A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
WO2013066835A3 (en) Compounds and methods
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013019561A8 (en) Nuclear transport modulators and uses thereof
JP2011037901A5 (cg-RX-API-DMAC7.html)
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
WO2012083122A8 (en) Inhibitors of influenza viruses replication
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
EA033054B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof